April 22nd 2024
Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Alvotech to Launch Pharmacokinetics Study for Denosumab Biosimilar
July 20th 2022The biosimilar candidate would reference Prolia, used in the treatment of osteoporosis in postmenopausal women and to treat bone loss in adult men and women who are at increased risk of fracture. It is also planned as a biosimilar for Xgeva, which is indicated to prevent skeletal fractures in patients with cancer.
Rituximab Biosimilars Prove Effective in Large B-Cell Lymphoma
July 14th 2022Abstracts from the European Hematology Association Congress 2022 confirmed comparable safety and effectiveness profiles between 2 rituximab biosimilars and the reference product (Rituxan) in patients with large B-cell lymphoma.
Survey: Most Patients Received Inadequate Information About Switching to a Trastuzumab Biosimilar
July 9th 2022A survey study found that many patients with breast cancer reported receiving inadequate information regarding switching from Herceptin to a trastuzumab biosimilar, with some patients reporting that they were never told a switch occurred or what a biosimilar was.
Henlius’ Pertuzumab Biosimilar Shows Similar PK Profile to Reference Product in First Human Study
July 2nd 2022In the first human study of Shanghai Henlius Biotech's pertuzumab biosimilar candidate (HLX11), investigators found similar pharmacokinetic (PK), safety, and immunogenicity profiles between the biosimilar and the reference product (Perjeta).
ASCO Studies Assess Biosimilar Substitution, Adoption in Oncology Practices
June 16th 2022Abstracts from the American Society of Clinical Oncology (ASCO) annual meeting took a look at the impact biosimilar substitution and increased biosimilar adoption had on spending within practices participating in value-based payment models and the Oncology Care Model.
Eye on Pharma: New Indication for Riabni, Organon and Henlius Partner on 2 Biosimilar Candidates
June 14th 2022The FDA granted a new indication for rheumatoid arthritis for Riabni, a rituximab biosimilar, and Organon and Shanghai Henlius Biotech entered into a licensing agreement for 2 oncology biosimilar candidates.
Similar Effectiveness, Safety of Biosimilar CT-P6 vs Reference Trastuzumab in Retrospective Study
June 13th 2022An analysis of retrospective data demonstrated comparable safety and efficacy profiles between CT-P6, a trastuzumab biosimilar, and Herceptin (reference trastuzumab) combined with chemotherapy and pertuzumab.
Contributor: No Good Deed Goes Unpunished—How PBM Mandates Increase Practice Variability
May 17th 2022Jeff Patton, MD, CEO and board member at OneOncology, dived into the controversial role that pharmacy benefit managers (PBMs) play in formulary decision-making and how PBMs impact biosimilar utilization.
Conference Posters Highlight Real-world Trends of Biosimilars, Reclassified Biologics
May 14th 2022Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting examined the real-world patterns of biosimilar utilization and the impact of products that have been reclassified as biologics on Medicaid spending.
AMCP Posters Highlight Clinical, Real-world Application of Trastuzumab, Infliximab Biosimilars
April 23rd 2022Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting highlighted the clinical similarity of a trastuzumab biosimilar compared with its reference product and real-world longitudinal application of infliximab biosimilars.
Prioritizing Reference Products Over Biosimilars Led to Millions in Missed Savings for Part D
April 20th 2022Medicare Part D plans missed out on between $84 million and $143 million in savings by not prioritizing the use of biosimilars over reference products, according to a report from the HHS Office of Inspector General.
Pegfilgrastim Biosimilars Provide Clinical, Economic Benefits to Prevent Febrile Neutropenia
April 18th 2022An analysis of real-world dosing and effectiveness of pegfilgrastim biosimilars found the clinical benefits of preventing febrile neutropenia in patients with intermediate to high risk come at acceptable financial costs compared with filgrastim biosimilars.
Fresenius Kabi Steps Up Its Biosimilar Game With Biosimilar Approval in Europe, Acquisitions
April 9th 2022Switzerland-based company Fresenius Kabi announced that its pegfilgrastim biosimilar received marketing authorization in Europe and that it has obtained a majority stake in biosimilar manufacturer mAbxience and acquired its subsidiary.
Biosimilar Competition and Utilization Uptake Have Driven Down Costs in the Oncology Space
April 1st 2022During a session at the Academy of Managed Care Pharmacy annual meeting, Yuqian Liu, PharmD, of Magellan Rx Management, highlighted strategies to encourage biosimilar utilization in the oncology space and the cost savings as a result.
Phase 3 Trial Confirms Equivalence Between Tuznue, Reference Trastuzumab in ERBB2+ Breast Cancer
March 23rd 2022An international phase 3 study of patients with erb-B2 receptor tyrosine kinase 2-positive (ERBB2+) breast cancer showed that Tuznue, a trastuzumab biosimilar, had comparable safety and efficacy to the reference product (Herceptin).